Abstract ND12: Discovery of PF-07220060, a potent and selective CDK4 inhibitor

药理学 医学 癌症研究
作者
Lars Anders,Gary M. Gallego
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (7_Supplement): ND12-ND12 被引量:4
标识
DOI:10.1158/1538-7445.am2024-nd12
摘要

Abstract PF-07220060 was developed based on the clinical need to improve efficacy and safety outcomes in patients treated with currently approved dual CDK4/6 inhibitors, including Palbociclib. Although all dual CDK4/6 inhibitors increase response rates and prolong disease control, they show common dose-limiting hematologic toxicities, foremost neutropenia. This poses challenges to provide these agents at doses necessary to extinguish cell cycling in tumors. Human ER+ breast cancer cells are highly dependent on CDK4 but not CDK6. By contrast, CDK4 is dispensable for human bone marrow derived cells, or cells enriched for neutrophil precursors or hematopoietic stem cells. This is primarily due to the compensatory role of CDK6 in these compartments. These observations prompted us to develop PF-07220060, an aminopyrimidine-based inhibitor, endowed with 20-fold and 4-fold increased selectivity for CDK4 over CDK6 when compared to Palbociclib and Abemaciclib/Ribociclib, respectively. CDK4-over-CDK6 selectivity is explained by G-loop conformational differences between the two kinases, with the G-loop of CDK4 being more flexible, assuming a more open conformation when bound to CDK4 selective versus non-selective inhibitors. PF-07220060 reduces dose-limiting neutropenia in beagle dogs by 15-fold when compared with Palbociclib, consistent with early clinical data obtained with PF-07220060. Higher tolerated plasma concentrations of PF-07220060 versus dual CDK4/6 inhibitors enable increased inhibition of CDK4 kinase activity in tumors. This translates to improved tumor growth inhibition across CDK4-driven models of human breast and prostate cancer at clinically relevant doses. Our work establishes proof-of-concept for CDK4 selective inhibition and introduces a best-in-class CDK4 inhibitor for treatment of HR+ HER2- breast cancer and other CDK4 dependent tumor types. Citation Format: Lars Anders, Gary Gallego. Discovery of PF-07220060, a potent and selective CDK4 inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr ND12.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
花随幽人落完成签到,获得积分10
刚刚
扎克斯完成签到,获得积分10
刚刚
科研通AI6.2的应助被Lila采纳,获得10
1秒前
1秒前
Buster发布了新的文献求助10
1秒前
e00ec发布了新的文献求助10
1秒前
coolru的应助被constanceFR采纳,获得10
1秒前
xiaole完成签到,获得积分10
1秒前
wangbq完成签到 ,获得积分10
2秒前
胖胖完成签到,获得积分10
2秒前
4秒前
欣喜香菇发布了新的文献求助10
4秒前
忧虑的牛排完成签到,获得积分10
5秒前
机灵奇迹完成签到,获得积分10
5秒前
别摆烂了完成签到,获得积分10
6秒前
陆lu完成签到,获得积分10
6秒前
7秒前
7秒前
大个的应助被神勇的曼文采纳,获得10
8秒前
8秒前
9秒前
打打的应助被司徒宝采纳,获得10
9秒前
uri发布了新的文献求助10
9秒前
369ninja的应助被青丝采纳,获得10
10秒前
所所的应助被wang采纳,获得10
10秒前
10秒前
李健的应助被AA采纳,获得10
10秒前
daomaihu发布了新的文献求助100
12秒前
哈哈哈完成签到,获得积分10
12秒前
吃猫的鱼发布了新的文献求助10
14秒前
14秒前
14秒前
荣离枯发布了新的文献求助10
14秒前
YU发布了新的文献求助10
14秒前
14秒前
惠1完成签到,获得积分10
15秒前
power发布了新的文献求助10
15秒前
传奇3的应助被wang采纳,获得10
15秒前
小薇薇完成签到,获得积分20
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175267
求助须知:如何正确求助?哪些是违规求助? 9567035
关于积分的说明 21789830
捐赠科研通 7769741
什么是DOI,文献DOI怎么找? 3431840
关于科研通互助平台的介绍 2556149
邀请新用户注册赠送积分活动 2477241